Rural hospital turns to GoFundMe to stay open

The only hospital in Polk County, Tennessee, has laid off 15 nurses, halted all inpatient care and started a crowdfunding campaign in hopes of raising $100,000.

The 25-bed Copper Basin Medical Center is “technically bankrupt,” according to its new CEO, Dan Johnson. While the emergency and outpatient departments will continue to operate, Johnson said staff cutbacks were necessary when the hospital couldn’t make payroll.

“It wouldn’t have been fiscally responsible or morally responsible to have people work without paying them every two weeks. And to raise capital, we need to reduce payroll,” he told STAT.

Former employees have complained they’re still owed paychecks, while Johnson said his efforts are focusing on keeping the hospital open on a day-to-day basis, “figuring out who to pay $200 or $300 for supplies.” After its billing vendor quit, the hospital started offering patients with overdue bills a chance to pay half their outstanding amount to get their remaining debt written off.

But so far, the GoFundMe campaign has only raised $845.

Read the full article at the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.